Repligen
RGEN
P/S ratio for Repligen (RGEN)
P/S ratio as of April 2024 (TTM): 14.6
According to Repligen 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 14.5618. At the end of 2023 the company had a P/S ratio of 15.7.
P/S ratio history for Repligen from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 15.7 | 34% |
| 2022 | 11.7 | -46.29% |
| 2021 | 21.8 | -23.72% |
| 2020 | 28.6 | 60.6% |
| 2019 | 17.8 | 49.33% |
| 2018 | 11.9 | 6.67% |
| 2017 | 11.2 | 12.2% |
| 2016 | 9.97 | -10.61% |
| 2015 | 11.2 | 9.27% |
| 2014 | 10.2 | 59.86% |
| 2013 | 6.39 | 103.04% |
| 2012 | 3.15 | -8.06% |
| 2011 | 3.42 | -37.77% |
| 2010 | 5.50 | -10% |
| 2009 | 6.11 | 45.49% |
| 2008 | 4.20 | -59.34% |
| 2007 | 10.3 | 60.41% |
| 2006 | 6.44 | -30.4% |
| 2005 | 9.25 | -9.44% |
| 2004 | 10.2 | -46.53% |
| 2003 | 19.1 | 66.56% |
| 2002 | 11.5 | -35.84% |
| 2001 | 17.9 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.46 | -83.12% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | 5.11 | -64.92% | 🇺🇸 USA |
 General Electric GE | 2.56 | -82.45% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2.00 | -86.29% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | 0.6097 | -95.81% | 🇺🇸 USA |
 Novavax NVAX | 0.8254 | -94.33% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | 7.25 | -50.23% | 🇺🇸 USA |
 Bio-Techne TECH | 8.79 | -39.61% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 6.35 | -56.41% | 🇺🇸 USA |
 Charles River Laboratories
CRL | 2.86 | -80.38% | 🇺🇸 USA |